News | November 06, 2024
Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Strengthening focus in Alzheimer's disease and neuroscience pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
